1. Introduction {#sec1}
===============

Antibiotic-loaded bone cements are used to fabricate spacers during two-stage exchange of knee and hip prostheses for the treatment of periprosthetic joint infection (PJI) \[[@B1]\]. During stage-one operation, the infected prosthesis is removed and a poly(methyl methacrylate) (PMMA) bone cement spacer is temporarily implanted. The spacer works as a drug delivery system for antibiotics in order to achieve high local concentrations \[[@B2]\]. Additionally, it stabilizes the joint during mobilization and prevents soft tissue contraction \[[@B3]\]. Antibiotic loading of the bone cement can be performed right before the mixing procedure (manually loaded) or during the industrial production of the powder component (premixed). The spacer is molded after initiation of the polymerization of the cement by mixing its powder and liquid.

To date, some bone cement brands that are intended for the use for fixation of total joint replacements are also used to fabricate spacers, one example being Palacos® R+G \[[@B4], [@B5]\]. At the same time, cement modifications with improved antibiotic elution are tested \[[@B6]\]. Recently, a bone cement brand, designed specifically for fabricating spacers (Copal® spacem), was launched. The powder of this brand includes calcium carbonate particles, which serve as both contrast agent and biodegradable porogen. Antibiotics are not premixed into Copal® spacem, with the intention that an appropriate amount of pathogen-adjusted antibiotic will be mixed with the powder of the cement just before spacer fabrication and implantation. Bitsch et al. reported improved antibiotic elution characteristics of Copal® spacem when a single antibiotic was added \[[@B7]\].*In vitro* testing has shown that combination of antibiotics in a spacer can induce synergistic antibiotic elution \[[@B2]\] and superior antibacterial effects \[[@B8]--[@B10]\]. The combination of gentamicin and vancomycin ensures effective action against a broad range of PJI-causing pathogens \[[@B11]\]. Thus, there are reports of clinical use of spacers fabricated using manual loading of the gentamicin premixed powder of Palacos® R+G with vancomycin \[[@B1], [@B4]\].

In the present study, we compared antibiotic elution and compressive strength of Copal® spacem when gentamicin and vancomycin were added (COP specimens) to those properties for Palacos® R+G when vancomycin was added (PAL specimens). For COP, the amount of gentamicin added is the same as it is premixed in Palacos® R+G. For both cements, the antibiotic(s) were added to the powder using manual mixing. The investigation involved determination of the influence of vancomycin loading on the aforementioned cement properties and the compression tests were run both prior to and following the end of the elution tests. We hypothesized that gentamicin and vancomycin elution from COP specimens are significantly higher than from PAL specimens at comparable compressive strengths.

2. Materials and Methods {#sec2}
========================

2.1. Specimen Preparation {#sec2.1}
-------------------------

Palacos® R+G (Heraeus Medical GMBH, Germany) contains premixed 0.8 g gentamicin sulphate (0.5 g active gentamicin). To produce equal gentamicin loading, 0.84 g gentamicin sulphate (0.5 g active gentamicin) (Caelo, Germany) was added to the powder of Copal® spacem (40 g) (Heraeus Medical GMBH, Germany). Then 2.05 g, 4.10 g, and 6.15 g vancomycin hydrochloride (Hikma Farmaceutica, Portugal) were added to the powder of Copal® spacem. The same amounts of vancomycin hydrochloride were added to the powder of Palacos® R+G. Thus, 6 cement formulations were used ([Table 1](#tab1){ref-type="table"}).

Manual loading was performed following the recommendations by Kuhn et al. The antibiotics were thoroughly ground in a mortar and then the cement powder was successively added while stirring \[[@B4]\]. After that, the mixture was combined with the liquid of the cement, to produce a dough which then was poured into a mold to yield short, cylindrical specimens (diameter and height = 6 mm and 12 mm, respectively). These specimens were used for both the elution and the compression tests.

2.2. Elution Tests {#sec2.2}
------------------

The specimen was immersed in 1.5 ml fetal calf serum (FCS), in ambient laboratory conditions (temperature = 22 ± 1°C) for four weeks. FCS was exchanged every 24 hours. Samples of the eluate were taken every 24 hours for the first 7 days as well as after 14 and 28 days and stored at -20°C for determination of antibiotic concentration. Vancomycin concentrations were measured in a clinical analyzer (Hitachi Analyzer, Roche, Germany) with a homogene enzyme immunoassay (Online TDM Vancomycin Cobas, Roche (upper limit of measurement 50.0 *μ*g/ml and lower limit of measurement 5.0 *μ*g/ml with coefficient of variance 1.1%--4.9%)). Gentamicin concentrations were measured in the same way with the CEDIA® Gentamicin II Assay (Microgenics, Germany (upper limit of measurement 12.0 *μ*g/ml and lower limit of measurement 0.00 *μ*g/ml with coefficient of variance 3.0--6.2% for gentamicin)). If the concentration exceeded the upper limit of measurement, the eluate was diluted with FCS, the measurement was repeated, and the true concentration was calculated. For each of the formulations, 6 specimens were tested.

2.3. Compression Tests {#sec2.3}
----------------------

The tests were conducted in accordance with the ISO 5883 \[[@B12]\] using a servohydraulic material testing machine (Z020, Zwick/Roell, Ulm, Germany), at a crosshead displacement of 10 mm/min. Tests were performed on two sets of specimens, prior to (n = 5) and immediately following the end of the elution test (n = 5).

2.4. Statistical Analysis {#sec2.4}
-------------------------

Results are presented as mean and 95% confidence intervals. The Kolmogorov-Smirnov-test was used to determine normal distribution of variables. Levene\'s test was used to test for equality of variances. T-tests for independent values were performed to identify significant differences in means. Significance was indicated if p \< 0.05. All of these tests were performed using a commercially-available software package SPSS 24.0 (SPSS Inc., USA).

3. Results {#sec3}
==========

The COP specimens produced significantly lower cumulative gentamicin concentrations than the PAL specimens at each of the 9 time points (p ≤ 0.005) ([Figure 1](#fig1){ref-type="fig"}).

The Cop2 specimens produced significantly higher (p ≤ 0.043) cumulative vancomycin concentrations after day 2. For the Cop4 specimens significantly higher (p ≤ 0.035) cumulative vancomycin concentrations were measured after day 1 and for the Cop6 specimens at every measurement (p ≤ 0.004). [Figure 2](#fig2){ref-type="fig"} depicts the cumulative vancomycin concentrations

Long term elution is crucial for the treatment with spacers. [Table 2](#tab2){ref-type="table"} depicts the determined antibiotic concentrations after 28 days.

Compressive strengths before elution tests were below the ISO 5883 recommended 70 MPa threshold, except for Pal4 ([Table 3](#tab3){ref-type="table"}).

After the elution tests, the compressive strength of Cop2 was significantly lower (p = 0.005) than of Pal2. The compressive strength of the COP and the PAL specimens loaded with 4 g and 6 g of vancomycin underwent significant reduction (p ≤ 0.014) during antibiotic elution.

4. Discussion {#sec4}
=============

Antibiotic-loaded PMMA bone cements are used as spacers to provide high local antibiotic concentrations and mechanical stability of the affected joint after removal of the infected prosthesis \[[@B2]\]. The bone cement Copal® spacem was recently introduced as a cement designed specifically for high antibiotic elution. However, data on antibiotic elution and mechanical properties of the Copal® spacem cement are lacking. The current study compared antibiotic elution and compressive strength of Copal® spacem and of Palacos® R+G as biantibiotic cements loaded with gentamicin and vancomycin.

For these biantibiotic formulations, we found lower gentamicin elution of the manually blended Copal® spacem compared to the gentamicin premixed Palacos® R+G. In contrast, Bitsch et al. found superior cumulative antibiotic elution from Copal® spacem in comparison to Palacos® R, when both these cements were manually monoantibiotic-loaded with gentamicin. In their study, vancomycin release displayed a slope of the cumulative antibiotic concentrations, which leveled earlier with decreasing amount of added vancomycin \[[@B7]\]. In accordance with these results, we found significant higher cumulative elutions but not higher vancomycin concentrations after 28 days for Cop2 and Cop4.

In the current investigation, manually gentamicin and vancomycin loaded Copal® spacem was compared to commercially available gentamicin premixed Palacos® R+G manually blended with vancomycin. Elution of Copal® spacem is enhanced by addition of calcium carbonate as a soluble porogen \[[@B7]\]. Such porogens enhance antibiotic elution by pore formation \[[@B6]\]. Although controversially discussed \[[@B13]--[@B15]\], premixed antibiotics are reported to be better eluted than manually loaded antibiotics \[[@B8], [@B16]\]. Ferraris et al. found larger inhibition zones around Palacos® R+G specimens compared to manually gentamicin loaded Palacos® R specimens, indicating higher antibiotic elution \[[@B8]\]. Comparable results were presented in the study by Lewis et al. demonstrating higher antibiotic elution from industrial loaded cements compared to manually loaded cements \[[@B17]\]. Thus, the elution enhancing effect of calcium carbonate in Copal® spacem did not compensate for the weaker elution of the manually loaded gentamicin compared to the premixed gentamicin. For the manually loaded vancomycin, the elution enhancing effect of calcium carbonate in Copal® spacem leads to higher cumulative antibiotic elution by increasing the initial burst release of vancomycin. However, high initial vancomycin elution goes along with enhanced vancomycin depletion. Consequently, the effect of improved vancomycin release by Copal® spacem fades by time in dependence of the amount of added antibiotic.

Compressive strength was reduced irrespectively of the amount of added antibiotic without significant differences between the COP and the PAL groups before the elution tests. After the elution tests, reduction of compressive strength was caused by void and crack formation due to antibiotic elution of the manually loaded antibiotics \[[@B18]\]. Beyond a critical antibiotic concentration, antibiotic elution leads to the development of a mechanically relevant percolation network causing significant reduction of compressive strength \[[@B16]\]. In our study, the specimens of both groups with 4 g and 6 g of vancomycin exceeded this critical antibiotic concentration. However, although the absolute amounts of antibiotics in the cement powders were the same for the corresponding groups, COP specimens had a higher proportion of manually added antibiotic than PAL specimens. The difference in compressive strength of the 2 g vancomycin groups shows that the critical antibiotic concentration of the manually added antibiotics for mechanically relevant percolation lies between Cop2 and Pal2.

The current study has a number of limitations. We examined antibiotic release by determination of concentrations, which does not allow conclusion on antimicrobial activity. Thus, we cannot state whether the higher antibiotic burst release of vancomycin from COP specimens is of advantage compared to the concentrations produced by PAL specimens. All measured concentrations exceeded the minimal inhibitory concentration of the most common pathogens for PJI, even after 28 days \[[@B19], [@B20]\]. After this time, antibiotic measurements were stopped, because concentrations fell below the lower limit of measurement for vancomycin. In contrast to antimicrobial testing, determination of concentrations was chosen for better comparability and the measurement method for its very low coefficient of variance. Furthermore, our study was limited to the antibiotics gentamicin and vancomycin. Other combinations need to be investigated, but the chosen combination is in clinical use \[[@B1], [@B4]\]. Finally, Copal® spacem has shown better wear behavior compared to Palacos® R*in vitro* \[[@B7]\]. This could reduce wear particle induced osteolysis, when used to fabricate articulating spacers. Copal® spacem might be advantageous for the treatment of PJI with a known pathogen as monoantibiotic-loaded spacer. However, if the pathogen is unknown, a biantibiotic-loaded spacer with vancomycin covering a broad spectrum of gram-positive and gentamicin covering a broad spectrum of gram-negative pathogens is warranted \[[@B11]\]. Our results are specifically relevant for this indication. For neither Copal® spacem nor Palacos® R+G, the addition of 4 g and 6 g of vancomycin can be recommended due to mechanical considerations \[[@B2], [@B21]--[@B23]\]. For the addition of 2 g of vancomycin, we found a higher initial burst release of vancomycin, but no significant difference of concentrations after 28 days. Additionally, significantly lower gentamicin concentrations were determined for Copal® spacem throughout the study. Based on these*in vitro* results, Copal® spacem is not of advantage for the use as a gentamicin and vancomycin biantibiotic-loaded, static spacer in comparison to Palacos® R+G.

5. Conclusion {#sec5}
=============

Copal® spacem demonstrated inferior gentamicin elution. Cumulative vancomycin elution was significantly higher for all COP specimens, whereas vancomycin concentrations after 28 days showed no relevant differences. We could not demonstrate consistent superior antibiotic elution from Copal® spacem in comparison to Palacos® R+G as a biantibiotic gentamicin and vancomycin loaded cement. Thus, our results do not favor Copal® spacem over Palacos® R+G for gentamicin and vancomycin biantibiotic-loaded spacers.
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###### 

Compositions of powder of the prepared specimen groups.

  Specimen group   Active gentamicin amount in g   Active vancomycin amount in g
  ---------------- ------------------------------- -------------------------------
  Pal2             0.5                             2.0
                                                   
  Pal4             0.5                             4.0
                                                   
  Pal6             0.5                             6.0
                                                   
  Cop2             0.5                             2.0
                                                   
  Cop4             0.5                             4.0
                                                   
  Cop6             0.5                             6.0

###### 

Comparison of determined antibiotic concentrations after 28 days sorted by specimen group and measured antibiotic.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Specimen group by amount of added vancomycin in g   Measured antibiotic   Antibiotic concentration for COP \   Antibiotic concentration for PAL \   p
                                                                            mean in *μ*g/ml (CI 95%)             mean in *μ*g/ml (CI95%)              
  --------------------------------------------------- --------------------- ------------------------------------ ------------------------------------ ---------
  2                                                   Gentamicin            2.46 (2.03 -- 2.91)                  5.21 (2.62 -- 7.80)                  *0.041*

                                                                                                                                                      

  4                                                   Gentamicin            2.97 (2.35 -- 3.59)                  4.93 (3.84 -- 6.03)                  *0.002*

                                                                                                                                                      

  6                                                   Gentamicin            2.53 (2.02 -- 3.03)                  4.08 (2.43 -- 5.73)                  *0.043*

                                                                                                                                                      

  2                                                   Vancomycin            5.52 (5.01 -- 6.02)                  5.52 (3.45 -- 7.59)                  1.000

                                                                                                                                                      

  4                                                   Vancomycin            12.03 (11.19 -- 12.88)               12.82 (6.80 -- 18.84)                0.754

                                                                                                                                                      

  6                                                   Vancomycin            17.73 (15.92 -- 19.55)               11.45 (8.41 -- 14.49)                *0.001*
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison of compressive strengths before and after elution tests sorted by specimen group.

  Specimen group   Compressive strength before elution  mean MPa (95% CI)   Comparison of groups   Compressive strength after elution mean MPa (95% CI)   before vs. after elution p   
  ---------------- -------------------------------------------------------- ---------------------- ------------------------------------------------------ ---------------------------- ---------
  Pal2             69.4 (66.8 -- 72.0)                                      0.193                  *0.005*                                                70.4 (67.3 -- 73.2)          0.486
  Cop2             66.9 (62.6 -- 71.1)                                      63.9 (60.1 -- 67.7)    0.173                                                                               
                                                                                                                                                                                       
  Pal4             70.7 (65.5 -- 76.0)                                      0.637                  0.805                                                  59.8 (57.5 -- 62.1)          *0.001*
  Cop4             69.5 (64.6 -- 74.4)                                      60.1 (57.0 -- 63.2)    *0.002*                                                                             
                                                                                                                                                                                       
  Pal6             67.7 (58.2 -- 77.1)                                      0.461                  0.279                                                  57.7 (53.8 -- 61.6)          *0.014*
  Cop6             65.1 (62.5 -- 67.7)                                      55.5 (52.1 -- 59.0)    *\< 0.000*                                                                          
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